Navigation Links
Main Street Capital Announces New Portfolio Investment
Date:9/14/2011

HOUSTON, Sept. 14, 2011 /PRNewswire/ -- Main Street Capital Corporation (NYSE: MAIN) ("Main Street") announced today that it has completed a new lower middle market portfolio investment totaling approximately $6.8 million in invested capital.

The investment was made to support the acquisition of the assets and business of a dedicated investigative facility (the "Company"), which conducts clinical trials for the pharmaceutical industry, by a group of private investors. Main Street's investment consists of $6.3 million in first lien secured debt and a $0.5 million direct equity investment.

Staffed by physicians and support personnel, the Company recruits and treats patients with later stage drugs in development by its pharmaceutical company clients. The Company's primary focus is on Phase II and Phase III metabolic disease trials, principally in diabetes, hypertension and obesity. The Company is headquartered in California.

ABOUT MAIN STREET CAPITAL CORPORATION

Main Street (www.mainstcapital.com) is a principal investment firm that primarily provides long-term debt and equity capital to lower middle market companies. Main Street's lower middle market investments are made to support management buyouts, recapitalizations, growth financings and acquisitions of companies that operate in diverse industry sectors and generally have annual revenues ranging from $10 million to $100 million.  Main Street seeks to partner with entrepreneurs, business owners and management teams and generally provides "one stop" financing alternatives within its lower middle market portfolio. Main Street also maintains a portfolio of privately placed, interest-bearing debt investments in middle market businesses that are generally larger in size than its lower middle market portfolio companies.

Contacts:
Main Street Capital Corporation
Dwayne L. Hyzak, Chief Financial Officer and Senior Managing Director
dhyzak@mainstcapital.com
713-350-6000

Dennard Rupp Gray & Lascar, LLC
Ken Dennard  |  ksdennard@drg-l.com
Ben Burnham |  bburnham@drg-l.com
713-529-6600


'/>"/>
SOURCE Main Street Capital Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dr. Ari Kiev to be Featured Speaker at Biotechnology Conference Wall Street Unplugged: The Trout Group Investor Seminar in New York July 30
2. Internal Fixation Systems to Sponsor and Exhibit at Wallstreet Spring Break Growth and Value Investor Conference in Fort Lauderdale, FL March 3-4, 2010
3. Water Street Healthcare Partners Signs Definitive Agreement to Sell Sierra Scientific Instruments to Given Imaging
4. 4-Star General-Former U.S. Drug Czar Barry McCaffrey Featured At Tacoma Treatment Solutions 5-Year Anniv: Mon. May 24, 11 a.m., 9500 Front Street, Lakewood WA 98499
5. Water Street Healthcare Partners Announces New Investment in Medical Specialties Distributors, LLC
6. Cardiogenesis Executive Chairman Paul J. McCormick Updates Commercial and Regulatory Progress in Interview With Wall Street Reporter, Available Online
7. ADVENTRX to Present at the Wall Street Analyst Forum 21st Annual Institutional Investor Conference on November 11
8. Water Street Healthcare Partners Acquires OraPharma, Inc.
9. TPI 2010 Shareholder Annual Meeting on 3/21/11 to Be Held at 100 Wall Street, near NYSE
10. Water Street Healthcare Partners Acquires MarketLab, Inc.
11. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)...  As the specialty pharmacy industry and the ... the revolutionary shift from volume-based to value-based care, ... patient outcomes and shaping the future of the ... from clinical trials and toward data that reveals ... therapy utilization in precise patient populations. Therigy ® ...
(Date:5/18/2017)... -- Bayer announced today that the latest research from across ... 53 rd Annual Meeting of the American Society ... Chicago . The ... and thyroid cancers, as well as lymphomas, and includes ... of copanlisib in patients with relapsed or refractory follicular ...
(Date:5/15/2017)... 2017 Enterin Inc., a privately-held CNS pharmaceutical company ... compounds to treat Parkinson,s disease (PD), has enrolled the first ... 1/2a randomized, controlled, multicenter study involving patients with PD and ... patients over a 9-to-12-month period. The first stage is open ... PD. Participating sites include Denver , ...
Breaking Medicine Technology:
(Date:5/24/2017)... , ... May 24, 2017 , ... ... of ExtraHop to its solutions portfolio. ExtraHop delivers an analytics-first approach, layered with ... every IT system, from the datacenter to the cloud to the edge. Through ...
(Date:5/24/2017)... ... 24, 2017 , ... The CFOs included on this list ... in the nation and help their organizations navigate the challenges in healthcare today. ... in developing successful hospital and health system strategy. , Becker's Hospital Review has ...
(Date:5/23/2017)... ... May 23, 2017 , ... MDLand International (MDLand), a ... today that its iClinic V12.2 solution has achieved approval from National Center for ... PCMH 2017 standards which emphasize team-based care with a significant focus on the ...
(Date:5/23/2017)... ... May 23, 2017 , ... Cambridge, MA, May ... since 2009, according to a Workers Compensation Research Institute (WCRI) study, a contrast ... North Carolina System: CompScope™ Benchmarks, 17th Edition looks at indemnity and medical ...
(Date:5/23/2017)... ... 2017 , ... London, May 23, 2017: Walter Schindler, the Founder and Managing ... Guest Speaker and Contributor to a weeklong series of classes, meetings, field trips and ... , Walter Schindler and SAIL Capital have received an increasing number ...
Breaking Medicine News(10 mins):